Abstract
INTRODUCTION: Malaria is a devastating infectious illness caused by protozoan Plasmodium parasites. The circumsporozoite protein (CSP) on Plasmodium sporozoites binds heparan sulfate proteoglycan (HSPG) receptors for liver invasion, a critical step for prophylactic and therapeutic interventions.
METHODS: In this study, we characterized the αTSR domain that covers region III and the thrombospondin type-I repeat (TSR) of the CSP using various biochemical, glycobiological, bioengineering, and immunological approaches.
RESULTS: We found for the first time that the αTSR bound heparan sulfate (HS) glycans through support by a fused protein, indicating that the αTSR is a key functional domain and thus a vaccine target. When the αTSR was fused to the S domain of norovirus VP1, the fusion protein self-assembled into uniform S 60-αTSR nanoparticles. Three-dimensional structure reconstruction revealed that each nanoparticle consists of an S 60 nanoparticle core and 60 surface displayed αTSR antigens. The nanoparticle displayed αTSRs retained the binding function to HS glycans, indicating that they maintained authentic conformations. Both tagged and tag-free S 60-αTSR nanoparticles were produced via the Escherichia coli system at high yield by scalable approaches. They are highly immunogenic in mice, eliciting high titers of αTSR-specific antibody that bound specifically to the CSPs of Plasmodium falciparum sporozoites at high titer.
DISCUSSION AND CONCLUSION: Our data demonstrated that the αTSR is an important functional domain of the CSP. The S 60-αTSR nanoparticle displaying multiple αTSR antigens is a promising vaccine candidate potentially against attachment and infection of Plasmodium parasites.
Original language | English |
---|---|
Pages (from-to) | 3087-3107 |
Number of pages | 21 |
Journal | International Journal of Nanomedicine |
Volume | 18 |
DOIs | |
Publication status | Published - 8 Jun 2023 |
Bibliographical note
Publisher Copyright:© 2023 Xia et al.
Funding
The research described in this study was supported by the National Institute of Allergy and Infectious Diseases (NIAID, R56 AI148426-01A1 to M.T.), Cincinnati Children’s Hospital Medical Center (CCHMC, Innovation Funds 2018-2020, GAP Fund 2020-2021, and Research Innovation and Pilot Grant 2020-2021 to M.T.), and the Center for Clinical and Translational Science and Training (CCTST) of the University of Cincinnati College of Medicine (Pilot Collaborative Studies Grant 2018-2019 to M.T.) that was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR001425).
Funders | Funder number |
---|---|
CCTST | |
Center for Clinical and Translational Science and Training | |
National Institutes of Health | UL1TR001425 |
National Institute of Allergy and Infectious Diseases | R56 AI148426-01A1 |
National Center for Advancing Translational Sciences | |
Cincinnati Children's Hospital Medical Center | 2020-2021 |
College of Medicine, University of Cincinnati | 2018-2019 |
Keywords
- Plasmodium
- S nanoparticle
- malaria
- malaria vaccine
- norovirus
- receptor binding domain
- αTSR domain